Oncology Biopharmaceuticals Market Size - By Product Type, By Cancer Type, By Route of Administration, By Drug Type, By Distribution Channel, Growth Forecast, 2025-2034

Oncology Biopharmaceuticals Market Size

The global oncology biopharmaceuticals market size was valued at USD 130.6 billion in 2024. The market is expected to grow from USD 139.4 billion in 2025 to USD 268.3 billion in 2034, at a CAGR of 7.5% during the forecast period according to the latest report published by Global Market Insights Inc.

The oncology biopharmaceuticals market is experiencing transformative development due to the increasing global burden of cancer and the need for more focused and personalized therapies. The American Cancer Society estimates that in 2022, there were about 20 million new cancer cases and 9.7 million cancer deaths globally. In 2050 there will be 35 million cases of cancer. In the U.S. more than 2 million new cases will be projected in 2025, with 618,000 deaths.
 

Oncology biopharmaceuticals are cancer treatments made from living (biological) cell substances and include monoclonal antibodies, CAR-T therapies, and immune checkpoint inhibitors. These are among the most innovative and personalized cancer care available. Key players such as Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, and AstraZeneca are at the forefront of this market. These companies are investing heavily in research and development and expanding their oncology pipelines. Pfizer’s acquisition of Seagen and the rise of AI-designed antibodies through partnerships such as Absci-AstraZeneca exemplify the sector’s momentum. Meanwhile, biosimilars and digital therapeutics are improving affordability and access, especially in emerging markets.  
 

The oncology biopharmaceutical market is projected to grow from USD 107.8 billion in 2021 to over USD 122.4 billion by 2023. This is largely due to developments in immunotherapy, next generation sequencing, and AI-driven drug discovery. Within the past year, the market has experienced significant new product introductions, including the approval of tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, dual-target CAR-T cells, and subcutaneous checkpoint inhibitors advancing access and lowering the treatment burden. These innovations fundamentally alter treatment approaches, particularly in hematologic malignancies and solid tumors. Oncology precision tools, such as DeepHRD and liquid biopsies, are squarely aimed at increasing early detection and targeting therapy to improve survival.
 

The market growth is attributed to government initiatives, investments in the healthcare sector, and the rapid progression of regulations. Oncology biopharmaceuticals are transforming cancer care and demonstrating the future of personalized medicine by tailoring treatment to the molecular profile of the patient.

Oncology Biopharmaceuticals Market Trends

• The oncology biopharmaceuticals industry is driven by developments in immunotherapy, targeted biologics, and personalized medicine. Such developments are needed as cancer treatments continue to be a primary focus for improving global health.
   
• According to the Global Cancer Observatory, lung cancer accounted for approximately 1.8 million deaths in 2022 and a five-year survival rate below 30%. Colorectal cancer is rising in incidence, especially among younger people, and has increased over 15% in people aged 25-49.  
   
• Moreover, the National Institutes of Health (NIH) predicts that pancreatic cancer, known for its aggressive nature and late diagnosis, will be the second leading cause of cancer deaths by the year 2030.  
   
• On the other hand, there is new chance for combination therapies in treatment of thyroid cancer, especially the anaplastic subtype, that in recent trials have shown an overall survival rate of more than 60% at 12 months. Additionally, rare and ultra-rare cancers together account for 20-25% of all cancer cases, which emphasizes the need for more treatment options.   
   
• New therapies such as bispecific antibodies, TIL therapies, and radioligand therapies are being developed to help treat advanced and resistant cancers. Circulating tumor DNA (ctDNA) has gained considerable interest in predicting outcomes, enabling earlier intervention and more proactive shifts in treatment.
   
• Artificial intelligence and machine learning have begun to impact the optimization of clinical trials and the drug discovery process, although its full potential in oncology is still unfolding. Additionally, the development of subcutaneous and oral biologics is focused on enhanced patient compliance and lessening the burden on the healthcare system.
   
• There is an increase in focus on real-world evidence along with the use of adaptive clinical trials, which work to speed up approvals and enhance post-market surveillance. This is especially useful with rare and pediatric oncology, where traditional trial frameworks have limitations.
   
• With the oncology biopharmaceuticals market focusing on the control of rare and complex cancers, there is a commitment to enhancing the quality of life and survivorship. This indicates a profound shift to precision, and innovation in the management of cancer. 
   

Oncology Biopharmaceuticals Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on product type, the oncology biopharmaceuticals market is divided into monoclonal antibodies, immune checkpoint inhibitors, cell and gene therapies, antibody-drug conjugates (ADCs), cancer vaccines, and other product types. The monoclonal antibodies segment accounted for 37.6% of the market in 2024. The segment is expected to exceed USD 96 billion by 2034, growing at a CAGR of 7% during the forecast period.   
 

• Monoclonal antibodies (mAbs) are pivotal in modern oncology. They are specific targeted biologic therapies that attach to certain antigens found on the surface of cancer cells. These biologics are designed to directly annihilate the tumor cells, block tumor growth signals, and activate the immune system to eradicate the cancer tissues. They are safer than traditional chemotherapies due to a reduced risk of off-target effects.
   
• Monoclonal antibodies are used for a wide variety of cancers, including breast, lung, and colorectal. With greatly improved survival rates, therapies such as trastuzumab, bevacizumab, and pembrolizumab have changed standard treatment practices. Innovation within the segment is rapid, featuring bispecific antibodies, antibody-drug conjugates (ADCs), and fully human antibodies.
   
• Recent advancements in the field include the application of artificial intelligence in antibody design, which accelerates the pace of development and increases binding specificity. Also, approaches that utilize circulating tumor DNA (ctDNA) and other biomarkers are improving the identification of appropriate patients for therapies as well as monitoring the therapies.
   
• The increasing burden of cancer coupled with rising demand for personalized medicine continues to propel growth in this segment. Though there are still challenges related to complexities in manufacturing and high costs, the development of biosimilars and subcutaneous formulations offers greater accessibility.    
   

Based on cancer type, the oncology biopharmaceuticals market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, leukemia and lymphoma, melanoma, ovarian and cervical cancer, and other cancer types. The lung cancer segment dominated the market in 2024 with a revenue of USD 37.5 billion.   
 

• Lung cancer continues to be the deadliest cancer on a global scale, with non-small cell lung cancer (NSCLC) making up around 85% of the cases. Most of the recent market shifts are a result of the growth of targeted therapies and the new developments in immuno-oncology. Transformative protocols are now possible due to EGFR, ALK and PD-L1 mutation targeted therapies.
   
• The introduction of new therapies, such as bispecific antibodies, immune checkpoint inhibitors, and other combination regimens, continues to extend survival in advanced-staged patients. EGFR mutation testing has become a standard practice in NSCLC, thus guiding the use of tyrosine kinase inhibitors. These new protocols have greatly improved patients’ quality of life and extended progression free survival.
   
• Early-stage lung cancer is also gaining attention. This is possible due to the advances in molecular diagnostics and liquid biopsy technology which allows for earlier detection and treatment.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on route of administration, the oncology biopharmaceuticals market is segmented into oral, parenteral, and other route of administration. The parenteral segment dominated the market in 2024 with a revenue of USD 92.6 billion.
 

• The parenteral route remains the dominant route of administration in oncology biopharmaceuticals. This is primarily due to the complex nature of biologics such as monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. These therapies often require intravenous (IV) or subcutaneous (SC) delivery to ensure bioavailability, stability, and rapid therapeutic action.
   

• For the high-dose or inpatient cancer treatment, the intravenous route is most used because it allows for accurate control of the drug delivery. However, patients and healthcare systems can be strained because it requires longer infusion times and the presence of specialized healthcare personnel and facilities.
   
• In response, the market is witnessing a shift toward subcutaneous delivery, especially for large-volume biologics. SC administration offers shorter injection times, improved patient comfort, and the potential for at-home treatment.
   
• Therapeutic innovations, such as wearable injectors and other formulation technologies, facilitate the transition of treatments from IV to SC delivery systems. For instance, SC treatments for daratumumab have dramatically decreased administration times from several hours to minutes. 
   

Based on drug type, the oncology biopharmaceuticals market is segmented into proprietary (branded), and biosimilars. The proprietary (branded) segment dominated the market in 2024 with a revenue of USD 104.1 billion and is expected to reach USD 208.8 billion in 2034. 
 

• Proprietary (branded) oncology biopharmaceutical drugs continue to dominate the market due to sustained innovation, strong therapeutic value, and rigorous protection of intellectual property rights. These branded oncology biopharmaceutical drugs have undergone extensive research and clinical trials and provide targeted cancer treatments.
   
• Branded oncology biologics have significantly improved survival rates and quality of life for patients with both solid tumors and hematologic malignancies.
   
• The high level of physician confidence in these treatments, along with established reimbursement policies in developed countries, enhances market value. Many of these branded therapies are designed for genetic mutations or biomarkers, consistent with the prevailing market emphasis on precision oncology.
   
• Branded oncology drugs, despite their high cost, continue to be in high demand because of their clinical efficacy and the absence of competition during the exclusive patent period. Nevertheless, this segment is starting to be challenged by biosimilars, particularly in cost-sensitive healthcare markets.
   

Based on distribution channel, the oncology biopharmaceuticals market is classified into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospital pharmacies companies segment dominated the market in 2024 and is expected to reach USD 167.6 billion by 2034.      

• Hospital pharmacies are essential in the distribution and administration of oncology biopharmaceuticals, particularly for complex therapies that need special care, storage, and administration. These are the therapies that include monoclonal antibodies, immune checkpoint inhibitors, and CAR-T cell therapies, which must be administered intravenously in controlled clinical settings.
   
• Due to the high cost and complexity of oncology biologics, hospital pharmacies are central to ensuring proper dosing, patient monitoring, and adherence to treatment protocols.
   
• They also streamline inventory management and supply coordination as oncologists prepare to administer life-saving therapies. Often, hospital pharmacies are the first point of access to newly approved cancer drugs, particularly those that require inpatient care or intensive monitoring.
   
• With the rise of personalized medicine, hospital pharmacies are increasingly involved in diagnostics and biomarker-based therapy selection. By overseeing investigational drugs and monitoring outcomes for patients in real-world studies, they provide crucial insight for clinical trials and real-world evidence generation. 
  
   

Looking for region specific data?

Download Free PDF

The North America oncology biopharmaceuticals market dominated around 43.8% of the revenue share in 2024.
 

• North America continues to face a high burden of cancer, with over 2.2 million new cancer cases and approximately 730,000 cancer-related deaths annually. According to Canadian Cancer Society, more than 230,000 new cases and 85,000 deaths are reported each year in Canada. The most prevalent cancers across both countries include breast, lung, prostate, and colorectal cancers. 
   
• North America has robust healthcare systems that support early detection, biomarker testing, and access to advanced oncology biopharmaceuticals. Canada’s universal healthcare model ensures broad access, while the U.S. leads in innovation and clinical trial activity.
   

The U.S. oncology biopharmaceuticals market was valued at USD 43.2 billion and USD 45.9 billion in 2021 and 2022, respectively. The market size reached USD 51.9 billion in 2024, growing from USD 48.8 billion in 2023.
 

• In 2024, there were over 2 million new cases of cancer, primarily breast, prostate, lung, and colorectal. With strong FDA approvals and active clinical trials, targeted therapies and immunotherapies have become prominent in treatment protocols.
   
• There are innovations in the use of artificial intelligence in diagnostics and drug development. Although there is significant innovation, unequal access to the new technologies remains, particularly for minority populations.  
   
• The U.S. has also made advanced personalized medicine, biosimilar products, and has investments to improve affordability and outcomes in CAR-T and TIL therapies.
   

Europe oncology biopharmaceuticals market accounted for USD 38.4 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe has 2.7 million new cancer cases every year and 1.3 million cancer deaths every year. The most common forms of cancer are breast, colorectal, lung, and prostate.
   
• Universal healthcare systems support access, though disparities remain between Western and Eastern Europe. Biosimilars are gaining traction, helping reduce treatment costs. However, high prices and regulatory delays still limit access in lower-income EU countries.  
   

Germany dominates the European oncology biopharmaceuticals market, showcasing strong growth potential.
 

• In 2022, Germany had 605,805 new cancer cases and 253,170 cancer deaths. As one of Europe’s most advanced oncology healthcare infrastructures, Germany has broad access to immunotherapies, targeted therapies, and comprehensive genomic testing options.   
   
• Germany is also a leader in biosimilars and clinical trials. Germany’s National Decade Against Cancer initiative facilitates the incorporation of precision medicine and the generation of real-world evidence.
   

The Asia Pacific oncology biopharmaceuticals market is anticipated to grow at the highest CAGR of 7.9% during the analysis timeframe.
 

• Asia Pacific has the highest cancer burden in the world, with over 10 million new cases and 50% of the world’s cancer deaths in 2023. Rapid urbanization and population aging, along with lifestyle changes, are the primary drivers of this trend.   
   
• The market is primarily led by China, India, and Japan, who are increasingly adopting targeted cancer therapies and immunotherapies. However, access, especially in rural areas, is still a challenge. Government support for precision medicine and genomic testing is strong further fueling the market.   
   
• The region is also a crucial point for oncology clinical trials and biosimilars, strengthening its position as a strategic innovator in cancer treatment on a global scale. 
   

China oncology biopharmaceuticals market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• China reported 4.8 million new cancer cases in 2022. The most common cancer in the country is lung cancer, which is attributed to the high prevalence of smoking. The rate of breast, colorectal, and prostate cancer are also on the rise. 
   
• The Health China 2030 government initiative focuses on improving early detection, prevention, and access to innovative treatments. There is a rapid adoption of targeted therapies and immunotherapies, thanks to local innovative biotech companies focused on developing PD-1 inhibitors and biosimilars.
   

Brazil leads the Latin American oncology biopharmaceuticals market, exhibiting remarkable growth during the analysis period.
 

• With the growing incidence of cancer, increasing investments in healthcare, and demand for precision medicine, Brazil’s oncology biopharmaceutical market continues its steady expansion. The country registers close to 483,000 new cancer cases per year. Urbanization, aging demographics, and lifestyle changes are contributing to this surge.
   
• Increased use of oral oncology medications in Brazil is also having a positive impact on outpatient care and patient adherence. Biosimilars are entering the market as patents expire, enhancing affordability and access.
   
• Further, global pharmaceutical companies are forming alliances with domestic players, which facilitates the rapid progression of clinical studies and the commercialization of advanced therapies.
   

Saudi Arabia oncology biopharmaceuticals market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Oncology biopharmaceutical market is one of the fast-growing sectors in Saudi Arabia due to the heightening prevalence of the disease, improved diagnostic tools and healthcare reforms initiated by the government. More than 28,000 new cases of the cancer are registered annually in Saudi Arabia.  
   
• Immunotherapies and targeted biologics are gaining traction, supported by increased investment in cancer centers and clinical research. Further, public-private partnerships are increasing the availability and affordability of treatment by allowing access to biosimilars. Alignment with the goals of Vision 2030, the market is changing to more personalized, predictive, and data-driven treatment for cancer.
   

Oncology Biopharmaceuticals Market Share

The oncology biopharmaceuticals industry presents a dynamic and moderately consolidated competitive landscape, shaped by the presence of global pharmaceutical giants, biotech innovators, and emerging cell therapy developers. Leading companies such as Merck, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, and Roche collectively account for approximately 55% of the market share. Their dominance is driven by blockbuster immunotherapies, robust oncology pipelines, and strategic investments in precision medicine and next-generation biologics.
 

To maintain leadership, these firms are pursuing multi-pronged strategies including acquisitions of biotech startups, expansion into radioligand and cell therapies, and partnerships with AI-driven drug discovery platforms. Their focus remains on expanding indications, accelerating clinical trials, and integrating real-world evidence to support regulatory approvals and market access.
 

Meanwhile, companies such as Adaptimmune, Legend Biotech, Arcellx, and Biocon are fueling innovation in T-cell therapies, biosimilars, and antibody-drug conjugates. These players are particularly active in emerging markets and niche oncology segments, where unmet needs and cost pressures drive demand for differentiated solutions.
 

The market continues to evolve with increasing adoption of personalized medicine, regulatory support for accelerated approvals, and growing demand for outpatient-friendly formulations. As oncology care shifts toward long-term disease control and survivorship, companies are expanding their portfolios to include tumor-agnostic therapies, companion diagnostics, and digital health integrations ensuring sustained innovation and global market growth.
 

Oncology Biopharmaceuticals Market Companies

Prominent players operating in the oncology biopharmaceuticals industry are as mentioned below:

• AbbVie
• Amgen
• AstraZeneca
• Bayer
• Biogen
• Bristol-Myers Squibb
• Eli Lilly
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Pfizer
• Sanofi
• Takeda Pharmaceutical
• Sandoz
• Biocon
• Celltrion
• Adaptimmune
• Legend Biotech
• Arcellx
   
• AbbVie

AbbVie is advancing oncology through a dual focus on hematologic malignancies and solid tumors. Its strength lies in antibody-drug conjugates (ADCs) and bispecific biologics, with standout assets such as Elahere for ovarian cancer and Teliso-V, a c-Met-targeted ADC for non-small cell lung cancer (NSCLC). AbbVie’s Epcoritamab, a CD3xCD20 bispecific antibody, is reshaping treatment for B-cell lymphomas. The company’s precision medicine strategy leverages biomarkers to match therapies with patient profiles, enhancing efficacy and minimizing toxicity. Its expanding pipeline includes over 30 investigational therapies across 20+ tumor types, supported by real-world data and AI-driven trial design.
 

•  Amgen

Amgen is a pioneer in T-cell engager (BiTE) technology, with Blincyto (blinatumomab) leading in acute lymphoblastic leukemia (ALL) and Imdelltra (tarlatamab) showing promise in small cell lung cancer. Its KRAS G12C inhibitor Lumakras, combined with Vectibix, is redefining treatment for metastatic colorectal cancer. Amgen’s oncology pipeline is powered by human genetic validation and molecular engineering, enabling breakthroughs in solid tumors and hematologic cancers.
 

• AstraZeneca

AstraZeneca’s oncology leadership is built on six scientific platforms, including DNA damage response (DDR), antibody-drug conjugates (ADCs), and immuno-oncology. Its triple-play of Imfinzi, Enhertu, and Camizestrant is transforming standards of care in lung, breast, and gastric cancers. Camizestrant, a next-gen SERD, uses ctDNA to guide treatment in HR+ breast cancer, while Enhertu is expanding HER2-targeted therapy across tumor types. AstraZeneca’s deep pipeline and strategic partnerships (e.g., Daiichi Sankyo, Merck) reinforce its dominance in precision oncology and combination therapies.
 

• Bristol-Myers Squibb (BMS)

BMS is a prominent player in immuno-oncology, with Opdivo (nivolumab) and Yervoy (ipilimumab) forming the backbone of combination regimens across multiple cancers. Its CAR-T therapy Breyanzi and bispecific antibody alliances, such as with BioNTech for BNT327 (targeting PD-L1 and VEGF), highlight its commitment to next-gen immunotherapies. BMS is also advancing protein degradation and targeted therapies such as Krazati for KRAS-mutated NSCLC. With a focus on earlier-stage cancers and tumor microenvironment modulation, BMS is redefining long-term survival strategies in oncology.
 

Oncology Biopharmaceuticals Industry News

• In February 2024, AbbVie acquired ImmunoGen, gaining access to the ADC Elahere and a pipeline targeting solid and hematologic tumors. This move strengthens AbbVie’s oncology portfolio with next-gen antibody-drug conjugates.
   
• In January 2024, Bristol Myers Squibb completed its acquisition of Mirati Therapeutics, adding the PRMT5 inhibitor MRTX1719 to its cancer pipeline. This strategy is expected to add value to the company’s business portfolio.
   
• In February 2024, BMS acquired RayzeBio, entering the radiopharmaceutical space. This move brings RayzeBio's lead product, RYZ101, a drug in Phase III trials for neuroendocrine tumors (NETs) and small cell lung cancer (SCLC), under BMS's oncology portfolio. 
   
• In March 2024, Novartis acquired MorphoSys, adding Monjuvi for diffuse large B-cell lymphoma to its hematologic oncology portfolio. The deal boosts Novartis’ presence in blood cancer therapies. 
   

The oncology biopharmaceuticals market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Monoclonal antibodies
• Immune checkpoint inhibitors
• Cell and gene therapies
• Antibody-drug conjugates (ADCs)
• Cancer vaccines
• Other product types  

Market, By Cancer Type

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia and Lymphoma
• Melanoma
• Ovarian and Cervical Cancer
• Other Cancer types

Market, By Route of Administration

• Oral
• Parenteral
• Other route of administration

Market, By Drug Type

• Proprietary (Branded)
• Biosimilars

Market, By Distribution channel

• Hospital pharmacies
• Drug stores and retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE